IXICO secures additional Huntington’s disease contracts

IXICO plc, the data analytics company delivering insights in neuroscience, announces that it has secured new contracts in Huntington’s disease (HD) clinical trials.

The new contracts include retrospective analysis of data sets for three Natural History Studies in Huntington’s disease with a new large pharma customer and a multicenter, open-label Phase II study in Huntington’s disease with an existing large pharma customer.

While these contracts to support HD clinical trials are not to the same scale as the £10.5m contract announced in April 2020, these additional contracts reflect the strong position IXICO has as a trusted neuroscience technology partner in this area. These contracts do not have significant impact on management's expectations of performance for the year but contribute to the Company's strong order book. In addition to this, these contracts are for early stage clinical trials and, as already demonstrated, IXICO has a strong track record of following clinical assets through to phase III where the contracts generate greater revenues.

Giulio Cerroni, Chief Executive Officer of IXICO, commented: "Huntington’s disease is a devastating rare neurological condition with unmet medical needs. IXICO has worked on several HD clinical studies since 2007 and is pleased to build further momentum in our mission to support our clients in delivering data analytics in these challenging areas of rare, neurodegenerative disease. Our services will enable clients to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression and drug development.”

 

For further information please contact:

IXICO plc

+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

 

 


Date: 22/10/2020